ReviewDrugs & aging2005
Disease-modifying therapies for osteoarthritis : current status.
Review in Drugs & aging, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00604539 (Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Nutraceutical supplements in management of pain and disability in osteoarthritis: a systematic review and meta-analysis of randomized clinical trials.Scientific reports · 2020Pooled it
- Chondroitin for osteoarthritis.The Cochrane database of systematic reviews · 2015Pooled it
- The effect of mobilization with movement on pain and function in patients with knee osteoarthritis: a randomized double-blind controlled trial.BMC musculoskeletal disorders · 2019Trial
- Efficacy and safety of loxoprofen hydrogel patch versus loxoprofen tablet in patients with knee osteoarthritis: a randomized controlled non-inferiority trial.Clinical rheumatology · 2016Trial
- Comparison of safety, efficacy and tolerability of dexibuprofen and ibuprofen in the treatment of osteoarthritis of the hip or knee.Wiener klinische Wochenschrift · 2014Trial
- Harnessing Photo-Energy Conversion in Nanomaterials for Precision Theranostics.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Anti-Inflammatory and Joint-Protective Effects of Blueberries in a Monosodium Iodoacetate (MIA)-Induced Rat Model of Osteoarthritis.Nutrients · 2025Article
- In vivo impact on rabbit subchondral bone of viscosupplementation with a hyaluronic acid antioxidant conjugate.BMC musculoskeletal disorders · 2024Article
- The pro-inflammatory cytokine IL-Iβ alteration by deer (Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence.International journal of molecular sciences · 2021Review
- IGF-1 Facilitates Cartilage Reconstruction by Regulating PI3K/AKT, MAPK, and NF-kB Signaling in Rabbit Osteoarthritis.Journal of inflammation research · 2021Article
- The Identified Hub Gene GlcN in Osteoarthritis Progression and Treatment.Computational and mathematical methods in medicine · 2021Article
- Tankyrase inhibition preserves osteoarthritic cartilage by coordinating cartilage matrix anabolism via effects on SOX9 PARylation.Nature communications · 2019Article
- The pathogenic role of connective tissue growth factor in osteoarthritis.Bioscience reports · 2019Review
- Active agents, biomaterials, and technologies to improve biolubrication and strengthen soft tissues.Biomaterials · 2018Review
- Do Neuroendocrine Peptides and Their Receptors Qualify as Novel Therapeutic Targets in Osteoarthritis?International journal of molecular sciences · 2018Review
- Chitosan in viscosupplementation: in vivo effect on rabbit subchondral bone.BMC musculoskeletal disorders · 2017Article
- Synthesis, Biological Evaluation, and Docking Studies of a Novel Sulfonamido-Based Gallate as Pro-Chondrogenic Agent for the Treatment of Cartilage.Molecules (Basel, Switzerland) · 2016Article
- Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT).ACS medicinal chemistry letters · 2015Article
- Posttraumatic knee osteoarthritis following anterior cruciate ligament injury: Potential biochemical mediators of degenerative alteration and specific biochemical markers.Biomedical reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis, the most common form of arthritis, is a debilitating progressive disease principally affecting the elderly. Osteoarthritis therapy has evolved in the past few decades from symptomatic treatment to possible disease-modifying solutions. In this paper, the pathophysiology of osteoarthritis is first reviewed, including an examination of the mechanisms underlying osteoarthritis and discussions of the roles of cartilage, synovial fluid and subchondral bone. The remainder of the paper discusses therapeutic approaches in current use and those in development, with special attention given to pharmacological treatments. Current approaches to treating osteoarthritis--i.e. medications; nonpharmacological modalities, such as physical therapy, exercise, weight management and orthotics; and (as a last resort) surgery--focus on reducing pain and improving (or at least maintaining) mobility. Drugs currently used to treat osteoarthritis fall into several categories: analgesics, NSAIDs, cyclo-oxygenase-2 (COX-2) inhibitors, corticosteroids, viscosupplementation, and symptomatic slow-acting drugs ('nutraceuticals'). The analgesics (paracetamol [acetaminophen] and opiates) have demonstrated less symptomatic efficacy than NSAIDs, while the latter have displayed mixed results in terms of joint space narrowing. COX-2 inhibitors have been demonstrated to be equal to or superior to NSAIDs in effectiveness. However, once considered a safer alternative, COX-2 inhibitors have become the subject of intense scrutiny since recent clinical evidence has cast suspicion on their cardiovascular safety profile. Injectable therapies, such as corticosteroids and viscosupplementation have elicited favorable short-term response but no long-term structural modification. On the other hand, the slow-acting drugs, especially chondroitin and glucosamine sulfate, have shown promising results. Also reviewed are other established and experimental therapies that seek to modify and/or even reverse the course of osteoarthritis. These include such medications as colchicine, bisphosphonates and hormones; dietary therapeutics, such as ginger extract and green tea; and such truly experimental treatments as matrix metalloproteinase inhibitors, cytokines, nitric oxide, growth factors and gene therapy. Osteoarthritis continues to be a difficult disorder to treat, as there is no cure as such and current treatments focus mainly on relieving pain and maintaining joint function. The search nevertheless continues for management regimens that can slow, alter or reverse the degenerative processes of osteoarthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.